Biosimilars
In a presentation led by Robert J. Bradway, Amgen chairman and chief executive officer, the company covered recent acquisitions, Repatha and Lumakras updates, biosimilars and its broader financial outlook.
Novartis unveiled plans to separate its generics and biosimilars arm, Sandoz, into a standalone entity, allowing both to pursue independent and more business-appropriate growth strategies.
Sandoz hopes its high-concentration formulation of an already greenlit biosimilar will be approved by the time AbbVie’s blockbuster drug Humira loses patent protection in the United States.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Swiss pharma giant Roche predicts a revenue slowdown related to its COVID-19 products and the increasing challenge of biosimilar drugs.
Amneal Pharmaceuticals received the green light from the U.S. Food and Drug Administration for bevacizumab-maly, a biosimilar to Genentech (Roche)’s Avastin.
San Jose-based Rani Therapeutics reported its fourth quarter and full-year 2021 financial results. The company hit major milestones this year, including the recent launch of the RaniPill High Capacity,
Releuko is expected to launch in the third quarter of 2022 as a treatment for neutropenia, a low white blood cell condition experienced by chemotherapy patients.
AbbVie and Alvotech have settled a case, granting Alvotech a non-exclusive license to all Humira-related patents in the United States beginning on July 1, 2023.
Biocon Biologics has acquired its partner Viatris’ biosimilars assets. The transaction is part of an effort to create a global, vertically-integrated biosimilars leader.
PRESS RELEASES